Initial development and preliminary validation of a new negative symptom measure: the Clinical Assessment Interview for Negative Symptoms (CAINS)

Courtney Forbes, Jack J Blanchard, Melanie Bennett, William P Horan, Ann Kring, Raquel Gur, Courtney Forbes, Jack J Blanchard, Melanie Bennett, William P Horan, Ann Kring, Raquel Gur

Abstract

As part of an ongoing scale development process, this study provides an initial examination of the psychometric properties and validity of a new interview-based negative symptom instrument, the Clinical Assessment Interview for Negative Symptoms (CAINS), in outpatients with schizophrenia or schizoaffective disorder (N = 37). The scale was designed to address limitations of existing measures and to comprehensively assess five consensus-based negative symptoms: asociality, avolition, anhedonia (consummatory and anticipatory), affective flattening, and alogia. Results indicated satisfactory internal consistency reliability for the total CAINS scale score and promising inter-rater agreement, with clear areas identified in need of improvement. Convergent validity was evident in general agreement between the CAINS and alternative negative symptom measures. Further, CAINS subscales significantly correlated with relevant self-report emotional experience measures as well as with social functioning. Discriminant validity of the CAINS was strongly supported by its small, non-significant relations with positive symptoms, general psychiatric symptoms, and depression. These preliminary data on an early beta-version of the CAINS provide initial support for this new assessment approach to negative symptoms and suggest directions for further scale development.

Conflict of interest statement

Conflict of interest

Dr. Blanchard has received honorarium from Merck for consultation. Dr. Gur has received investigator initiated grants from Astra Zeneca and Pfizer; honorarium from Astra Zeneca and Pfizer for a lecture and from Merck for consultation.

Copyright © 2010 Elsevier B.V. All rights reserved.

References

    1. Addington D, Addington J, Atkinson M. A psychometric comparison of the Calgary depression scale for schizophrenia and the Hamilton depression rating scale. Schizophr Res. 1996;19:205–212.
    1. Addington D, Addington J, Schissel B. A depression rating scale for schizophrenics. Schizophr Res. 1990;3:247–251.
    1. Alphs LD, Summerfelt A, Lann H, Muller RJ. The negative symptom assessment: a new instrument to assess negative symptoms in schizophrenia. Psychopharmacol Bull. 1989;25:159–163.
    1. Andreasen NC. Negative symptoms in schizophrenia: Definition and reliability. Arch Gen Psychiatry. 1982;39:784–788.
    1. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS) Iowa City, IA: The University of Iowa; 1984.
    1. Birchwood M, Smith J, Cochran R, Wetton S, Copestake S. The social functioning scale: the development and validation of a new scale of social adjustment for use in family intervention programs with schizophrenic patients. British J Psychiatry. 1990;157:853–859.
    1. Blanchard JJ, Cohen AS. The structure of negative symptoms within schizophrenia: implications for assessment. Schizophr Bull. 2006;32(2):238–245.
    1. Blanchard JJ, Kring AM, Horan WP, Gur R. Toward the next generation of negative symptom assessments: the collaboration for the advancement of negative symptom assessment in schizophrenia. Schizophr Bull. (in press)
    1. First M, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P) New York: Biometrics Research Department, New York State Psychiatric Institute; 2001.
    1. Gard DE, Germans-Gard M, Kring AM, John OP. Anticipatory and consummatory components of the experience of pleasure: a scale development study. J. of Personality. 2006;40:1086–1102.
    1. Gard DE, Kring AM, Gard MG, Horan WP, Green MF. Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure. Schizophr Res. 2007;93:253–260.
    1. Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria. Biol Psychiatry. 2004;56(5):301–307.
    1. Horan WP, Kring AM, Blanchard JJ. Anhedonia in schizophrenia: a review of assessment strategies. Schizophr Bull. 2006;32(2):259–273.
    1. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–271.
    1. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter W. The schedule for the deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30:119–123.
    1. Kirkpatrick B, Fenton W, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:296–303.
    1. Kurtz M, Mueser K. A meta-analysis of controlled research on social skills training for schizophrenia. J Consulting and Clinical Psych. 2008;76:491–504.
    1. Lachar D, Espadas A, Bailey SE. The Brief Psychiatric Rating Scale: Contemporary applications. In: Maruish M, editor. The Use of Psychological Testing for Treatment Planning and Outcomes Assessment: Instruments for Adults. Vol 3. Mahwah, NJ: Lawrence Erlbaum Associates; 2004. pp. 153–190.
    1. Leucht S, Arbter D, Engel R, Kissling W, Davis J. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. 2009;14:429–447.
    1. Montgomery SA, Zwieten-Boot B. ECNP consensus meeting. Negative, depressive, and cognitive symptoms of schizophrenia. Nice, March 2004; European Neuropsychopharmacology; 2004. pp. 70–77.
    1. Mueser KT, Sayers SL, Schooler NR, Mance RM, Haas GL. A multisite investigation of the reliability of the Scale for the Assessment of Negative Symptoms. Am J Psychiatry. 1994;151:1453–1462.
    1. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812.
    1. Williams JBW, Gibbon MF, First MB, Spitzer RL, Davies M, Borus J, Howes MJ, Kane J, Pope HG, Rounsaville B, Wittchen H. The Structured Clinical Interview for DSM-III-R (SCID): multisite test-retest reliability. Arch Gen Psychiatry. 1992;42:630–636.
    1. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behavior therapy for schizophrenia: Effect sizes, clinical models, and methodological rigor. Schizophr Bull. 2008;34:523–537.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere